On this basis, this review systematically summarizes the pharmacokinetic evidence and biological basis of long-term in vivo accumulation of platinum-based chemotherapeutic agents, elaborates on the mechanisms of organ toxicity mediated by platinum accumulation, clarifies the core association between insufficient platinum accumulation in tumor cells and chemoresistance, and finally concludes the key challenges and future research directions in this field, aiming to provide a theoretical basis for individualized adjustment of clinical chemotherapy regimens, early screening and intervention of long-term toxicity caused by platinum accumulation, and long-term health management of cancer survivors
While these findings are promising, it is crucial to emphasize that clinical research on MOTS-c in humans remains limited
The FDA itself is explicit that compounded drugs are not FDA-approved, and that it does not review compounded formulations for safety, effectiveness, or manufacturing quality before they reach a patient
in fact, their weight reduction was less pronounced than that of those on the lower dose